Thymic stromal lymphopoietin as a novel mediator amplifying immunopathology in rheumatic disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26163286.
- Also identified by DOI 10.1093/rheumatology/kev241.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thymic stromal lymphopoietin (TSLP) is an IL-7-related cytokine that has been studied extensively in atopic diseases and more recently in various rheumatic disorders. It is involved in T cell development in the thymus and promotes homeostatic T cell expansion by classical dendritic cells. However, deregulated TSLP expression in various rheumatic diseases has implicated this cytokine as a strong mediator in immunopathology. Overexpressed TSLP induces strong T cell activation and production of pro-inflammatory cytokines in human cells and animal models for RA, SSc and LN, underscoring the therapeutic potential of targeting the TSLP-TSLP receptor axis.
Medical subject headings
- Cytokines
- Rheumatic Diseases